Psoriasis patients may cut biologic doses without Flare-Ups
NCT ID NCT04340076
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study tested whether psoriasis patients with well-controlled disease can safely reduce their dose of IL17 or IL23 inhibitor biologics without causing flare-ups. 244 adults with stable psoriasis (clear or almost clear skin for at least 6 months) were randomly assigned to either dose reduction or usual care. The goal was to see if dose reduction was as effective as standard dosing at keeping psoriasis under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AZ Maria Middelares
Ghent, Belgium
-
AZ St Lucas
Ghent, Belgium
-
Amphia Hospital
Breda, Netherlands
-
Bravis hospital
Bergen op Zoom, Netherlands
-
CHU Liege
Liège, Belgium
-
Catharina hospital
Eindhoven, Netherlands
-
Dermatologie Maldegem
Maldegem, Belgium
-
Erasmus MC
Rotterdam, Netherlands
-
Ghent University Hospital
Ghent, 9000, Belgium
-
Maastricht UMC
Maastricht, Netherlands
-
Máxima Medisch Centrum
Veldhoven, Netherlands
-
Radboudumc
Nijmegen, 6500HB, Netherlands
-
Slingeland hospital
Doetinchem, Netherlands
-
UCL Saint Luc
Leuven, Belgium
-
ULB Erasme
Brussels, Belgium
-
UMC Groningen
Groningen, Netherlands
-
UMC Utrecht
Utrecht, Netherlands
-
UZ Leuven
Leuven, Belgium
-
Ziekenhuisgroep Twente
Almelo, Netherlands
Conditions
Explore the condition pages connected to this study.